References
- Frank ST, Weg JG, Harkleroad LE, Fitch RF. Pulmonary dysfunction in rheumatoid disease. Chest 1973;63:27–34.
- Cervantes-Perez P, Toro-Perez AH, Rodriguez-Jurado P. Pulmonary involvement in rheumatoid arthritis. J Am Med Assoc 1980; 243:1715–19.
- Bongartz T, Nannini C, Medina-Velasquez YF, Achenbach SJ, Crowson CS, Ryu JH, Incidence and mortality of interstitial lung disease in rheumatoid arthritis: a population-based study. Arthritis Rheum 2010;62:1583–91.
- Hakala M. Poor prognosis in patients with rheumatoid arthritis hospitalized for interstitial lung fibrosis. Chest 1988;93:114–18.
- Koduri G, Norton S, Young A, Cox N, Davies P, Devlin J, Interstitial lung disease has a poor prognosis in rheumatoid arthritis: results from an inception cohort. Rheumatology (Oxford) 2010;49:1483–9.
- Olson AL, Swigris JJ, Sprunger DB, Fischer A, Fernandez-Perez ER, Solomon J, Rheumatoid arthritis–interstitial lung disease-associated mortality. Am J Respir Crit Care Med 2010;183:372–8.
- Dixon WG, Hyrich KL, Watson KD, Lunt M, Symmons DP. Influence of anti-TNF therapy on mortality in patients with rheumatoid arthritis-associated interstitial lung disease: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2010;69:1086–91.
- Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM, Retamozo S, Bove A, Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases. Semin Arthritis Rheum 2011 Jan 28; [Epub ahead of print], doi:10.1016/j.semarthrit.2010.11.002.
- Wagner SA, Mehta AC, Laber DA. Rituximab-induced interstitial lung disease. Am J Hematol 2007;82:916–19.
- Gallelli L, Falcone D, Pelaia G, Renda T, Terracciano R, Malara N, Interleukin-6 receptor superantagonist Sant7 inhibits TGF-beta-induced proliferation of human lung fibroblasts. Cell Prolif 2008;41:393–407.